Cardiff Oncology Inc. (NASDAQ:CRDF) on Tuesday said that it filed a lawsuit against Nerviano Medical Sciences (NMS), disputing NMS's claim that Cardiff materially breached their licensing agreement for onvansertib.

onvansertib (PCM-075) - Cardiff Oncology

May 20, 2026